Home Newsfeeds U.S. in Talks with Taiwan to Co-produce American Weapons

News

U.S. in Talks with Taiwan to Co-produce American Weapons

-Nikkei https://asia.nikkei.com/Politics/International-relations/U.S.-in-talks-with-Taiwan-to-co-produce-American-weapons-sources

byCharles Gross

October 19, 2022

1 minute read

-Nikkei

https://asia.nikkei.com/Politics/International-relations/U.S.-in-talks-with-Taiwan-to-co-produce-American-weapons-sources

“Philadelphia Fed President Harker Advocates Holding Interest Rates ‘Where They Are'” – CNBC

By Benzinga Newsdesk

October 13, 9:15 AM

https://www.cnbc.com/2023/10/13/philadelphia-fed-president-harker-advocates-holding-interest-rates-where-they-are.htmlPhiladelphia Federal Reserve President Patrick Harker said Friday he thinks the central bank can stop

SPY

Amazon Accused Of Duping Consumers Into Prime Subscriptions By FTC: Reuters

By Benzinga Newsbot

June 22, 12:54 AM

The U.S. Federal Trade Commission (FTC) has accused Amazon.com Inc. (NASDAQ:AMZN) of enrolling millions of consumers into its…

AMZN

CrowdStrike Holdings Sees Q2 EPS $0.98-$0.99 Vs $0.91 Est.; Revenue $958.3M-$961.2M Vs $954.43M Est.; FY25 EPS $3.93-$4.03 Vs $3.91 Est.; Revenue $3.976B-$4.011B Vs $3.97B Est.

By Benzinga Newsdesk

June 4, 4:08 PM

Financial OutlookCrowdStrike is providing the following guidance for the second quarter of fiscal 2025 (ending July 31, 2024) and increasing its guidance for fiscal year 2025 (ending January 31, 2025).Guidance for

CRWD

FDA Clears Akouos’ Gene Therapy Trial For Genetic Form Of Hearing Loss

By Vandana Singh

September 13, 9:53 AM

The FDA has signed off Akouos Inc’s (NASDAQ:AKUS) Investigational New Drug application to initiate a Phase 1/2 trial of AK-OTOF, gene…

AKUS

U.S. in Talks with Taiwan to Co-produce American Weapons

Related Posts

“Philadelphia Fed President Harker Advocates Holding Interest Rates ‘Where They Are'” – CNBC

Amazon Accused Of Duping Consumers Into Prime Subscriptions By FTC: Reuters

CrowdStrike Holdings Sees Q2 EPS $0.98-$0.99 Vs $0.91 Est.; Revenue $958.3M-$961.2M Vs $954.43M Est.; FY25 EPS $3.93-$4.03 Vs $3.91 Est.; Revenue $3.976B-$4.011B Vs $3.97B Est.

FDA Clears Akouos’ Gene Therapy Trial For Genetic Form Of Hearing Loss